retatrutide phase 2 trial type 2 diabetes results 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Test results on a popular
Pay in 4 interest-free payments of $7.19 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12







00188-2/asset/060af149-96d8-44a2-9e4d-318ecc8ae69e/main.assets/gr1_lrg.jpg)



















